Median OS values were similar for bevacizumab and high-dose linifanib ( bevacizumab , 16.5 months [ 95 % CI , 13.0-not available ] ; high-dose linifanib , 16.4 months [ 95 % CI , 11.9-21 .7 ] ; low-dose linifanib , 12.0 months [ 95 % CI , 10.1-13 .0 ] ) .